Daniel A. Lang

Daniel A. Lang

Daniel A. Lang
New York
+1 212 459 7095

Daniel Lang, a partner in Goodwin’s Technology and Life Sciences group, has extensive experience advising high-growth technology and life sciences companies and investors that focus on these companies. His practice spans the corporate lifecycle – from start-up formations to seed, venture capital and growth equity financings to mergers and acquisitions, IPOs and other capital markets transactions. Mr. Lang also regularly advises clients on corporate governance, securities law compliance and other external “general counsel” matters. Mr. Lang represents both companies and investors in a variety of industries, including e-commerce, retail and consumer products, cosmetics and fashion, media and entertainment, consumer and enterprise software, AI, adtech, fintech, insurtech, proptech, medtech, digital health, wellness, healthcare and biotechnology.


Mr. Lang’s representative clients include private companies: Glossier, Thrive Global, Paperless Post, Pond5, Avvir, Prevu, BetMGM, Biteable, Celtra, Chord Commerce, Botanisol Analytics, Coderbyte, Digital Power Optimization Partners, Instant Teams, JLo Beauty & Lifestyle, Novakid, Ostendio, Revivn, Noteworth, Nirvana Health, Megaphone TV, Wave Sports + Entertainment, Carebridge, Hibercell, KaloCyte, PhyNet Dermatology, Pyramid Biosciences, TARA Biosystems, ARCH Oncology, and Linkwell Health; public companies: Codiak BioSciences, Foundation Medicine, Chiasma and Allena Pharmaceuticals; and investment funds: Glasswing Ventures, Vivo Capital, Perceptive Advisors, Bain Capital Ventures, B Capital, Macquarie Capital, Norrsken VC, Revelation Partners, Urgent VC, Walter Ventures, InterWest Partners and Hermed Capital.

Representative Matters

  • Pond5 in its acquisition by Shutterstock
  • Tara Biosystems in its acquisition by Valo Health
  • Celtra in its acquisition by Symphony Technology Group
  • Talla in its acquisition by Seva
  • StreetLinx in its acquisition by Symphony
  • Citus Health in its acquisition by Brightree, a subsidiary of ResMed
  • arfa in its acquisition of Yaguara
  • Hibercell in its acquisition of Biothera Pharmaceuticals’ Imprime PGG program 
  • Thrive Global in its acquisition of ZP Group and partnership with Walmart 
  • Thrive Global in its acquisition of Boundless Mind
  • Syntimmune in its acquisition by Alexion Pharmaceuticals
  • Aspire Health in its acquisition by Anthem
  • Orchard Platform in its acquisition by Kabbage
  • Glossier in its acquisition of Dynamo E-Media 
  • Thar Pharmaceuticals in its acquisition by Grünenthal
  • Songza in its acquisition by Google
  • M5 Networks in its acquisition by ShorTel
  • XGraph in its acquisition by Add This (formerly Clearspring)
  • Fidelis Security Systems in its acquisition by General Dynamics
  • Nomi Technologies in its acquisition by Brickstream
  • Tagman in its acquisition by Ensighten
  • EveryScreen Media in its acquisition by Media6Degrees
  • Fairhaven Capital in the acquisition of its portfolio company, CrowdTwist, by Oracle

  • Codiak BioSciences in its $83 million initial public offering and $66 million follow-on offering
  • Foundation Medicine in its (i) $120 million initial public offering, (ii) collaboration and equity transaction with Roche, with total value in excess of $1 billion and (iii) sale of the remaining minority interest to Roche for $2.4 billion
  • Ocera Therapeutics in its (i) acquisition by Mallickrodt for up to $117 million in upfront cash and contingent (CVR) consideration, (ii) $28 million PIPE financing, (iii) $25 million public offering and (iv) $25 million “at the market” offering facility
  • Allena Pharmaceuticals in its $75 million initial public offering
  • Chiasma in its (i) $102 million initial public offering, (ii) $34.5 million follow-on offering, (iii) $55 million follow-on offering, (iv) $70 million follow-on offering and (v) acquisition by Amryt
  • The underwriters in (i) the $184 million initial public offering, (ii) a $116 million follow-on offering, (iii) a $230 million follow-on offering, (iv) a $200 million “at the market” offering facility and (v) a $200 million convertible note offering of Intrexon
  • Vivo Capital in investments in ASLAN Pharmaceuticals, BioPharmX, Strongbridge Pharma, Kadmon, MEI Pharma, Sierra Oncology and Selecta BioSciences
  • Intralinks, Tranzyme and Tengion in their initial public offerings

  • Glossier in various financings with participation by Lone Pine Capital, Institutional Venture Partners, Thrive Capital, Forerunner Ventures and Index Ventures
  • Thrive Global in various financings with participation by Kleiner Perkins, Owl Ventures, JAZZ Venture Partners, IVP, Marc Benioff, Ray Dalio and Kevin Durant
  • arfa in its financings by Forerunner, Index, White Star Capital, Thrive, Box Group and others
  • Chord Commerce in its financing by Eclipse Ventures and Foundation Capital
  • Instant Teams in its financing led by Tiger Global
  • Avvir in various financings from investors that included Trust Ventures, Khosla Ventures, LocalGlobe, MetaProp NYC and Stacked Capital
  • Biteable in its Series A financing led by Cloud Apps Capital Partners
  • Prevu in its financing led by Corigin Ventures
  • Celtra in various financings with participation by WPP, Unilever, Grandbanks Capital and Fairhaven Capital
  • Digital Power Optimization Partners in its financing led by NYDIG
  • Orchard Platform in its financing led by Thrive Capital, Spark Capital and Canaan Partners
  • Hubble Contacts in various financings with participation by First Mark Capital, Two River, Wildcat Capital Management, Founders Fund, Greycroft and Colgate
  • Aircall in various financings with participation by Draper Esprit, Next World Capital, Balderton Capital and eFounders
  • Linkwell Health in various financings with participation by HLM Venture Partners and Spark Capital
  • Even Financial in its financing led by Canaan Partners and Lerer Hippeau Ventures
  • Pond5 in its financing by Accel Partners and Stripes Group
  • Paperless Post in various financings with participation by August Capital, Sherpalo Ventures, RRE Ventures, Mousse Partners and Top Tier
  • Megaphone TV in its financing led by Softbank Korea

  • Glasswing Ventures in various private investments, including Plannuh, Narrative, Talla, ZyloTech, Inrupt, ChaosSearch, askfora, Verusen, Elios, Narrative I/O, Labviva
  • Perceptive Advisors in various investments, including Dynacure, Athira Pharma, Kindbody, Freenome and AavantiBio
  • B Capital in various investments, including Lively, Hotspot Therapeutics, OncoMyx and Triumvira Immunologics
  • InterWest and Orbimed, as lead investors, in a $32 million investment in Avedro
  • Hermed Capital in its investments in Prognos and Spineology
  • Macquarie Capital in various investments and strategic collaborations

Professional Activities

Mr. Lang is a frequent lecturer at the Cardozo Tech Law Start Up Clinic, Columbia Business School, Columbia Law School, Cornell Tech, Food-X and eLab NYC on venture financings and other elements of start-up law.




Benjamin N. Cardozo School of Law

(cum laude)


Tufts University

(magna cum laude)



  • New York
  • New Jersey

Recognition & Awards

Mr. Lang was named a New York Metro Rising Star by Super Lawyers . In law school, Mr. Lang was an articles editor of the Cardozo Law Review.